PMV Pharmaceuticals Stock Rating Upgraded by Evercore

Investment firm cites strong potential for biotech company's lead cancer drug candidate

Apr. 14, 2026 at 9:56am

Got story updates? Submit your updates here. ›

An extreme close-up of a complex, industrial pharmaceutical manufacturing machine, with its intricate metallic components and mechanisms filling the frame in shades of silver, steel, and gunmetal grey, conveying a sense of power and precision in the production of new cancer treatments.Precision engineering and advanced manufacturing capabilities are critical to the development of innovative cancer therapies like PMV Pharmaceuticals' lead drug candidate.Princeton Today

Evercore, a leading investment research firm, has upgraded its rating on shares of PMV Pharmaceuticals (NASDAQ: PMVP) to a 'strong buy' recommendation. The upgrade comes as the company continues to advance its lead drug candidate, PC14586, a small molecule therapy targeting a specific p53 gene mutation found in various cancer types.

Why it matters

The upgrade from Evercore is a positive signal for PMV Pharmaceuticals, which has been working to develop innovative precision oncology treatments. If successful, PC14586 could provide a new therapeutic option for cancer patients with the Y220C p53 mutation, an area of high unmet medical need.

The details

In its research note, Evercore cited the progress PMV Pharmaceuticals has made with PC14586, including ongoing clinical trials evaluating the drug's safety and efficacy. The investment firm believes the therapy has significant commercial potential if it can demonstrate positive results in late-stage studies. Separately, Weiss Ratings maintained a 'sell' recommendation on PMV's stock.

  • PMV Pharmaceuticals stock closed at $1.35 per share on Monday, April 14, 2026.
  • The company's 52-week trading range is $0.81 to $1.88 per share.

The players

Evercore

A leading independent investment research and advisory firm.

PMV Pharmaceuticals

A clinical-stage precision oncology company developing small molecule therapies that target p53 gene mutations in cancer.

PC14586

PMV Pharmaceuticals' lead drug candidate, a small molecule that corrects the Y220C p53 mutation and restores wild-type p53 function.

Weiss Ratings

An independent investment research firm that provides stock ratings and analysis.

Got photos? Submit your photos here. ›

What’s next

PMV Pharmaceuticals will continue to advance its clinical trials for PC14586, with investors closely monitoring the drug's progress and potential regulatory approvals.

The takeaway

The Evercore upgrade underscores the promise of PMV Pharmaceuticals' precision oncology approach and its lead asset, PC14586, which targets a specific p53 gene mutation found in various cancer types. If successful, the therapy could provide a new treatment option for patients with limited therapeutic options.